Nanocarrier Lipid Composition Modulates the Impact of Pulmonary Surfactant Protein B (SP-B) on Cellular Delivery of siRNA
Two decades since the discovery of the RNA interference (RNAi) pathway, we are now witnessing the approval of the first RNAi-based treatments with small interfering RNA (siRNA) drugs. Nevertheless, the widespread use of siRNA is limited by various extra- and intracellular barriers, requiring its enc...
| Main Authors: | Roberta Guagliardo, Pieterjan Merckx, Agata Zamborlin, Lynn De Backer, Mercedes Echaide, Jesus Pérez-Gil, Stefaan C. De Smedt, Koen Raemdonck |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-08-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/11/9/431 |
Similar Items
-
Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery
by: Wanyi Tai
Published: (2019-06-01) -
A Multifunctional Hybrid Nanocarrier for Non-Invasive siRNA Delivery to the Retina
by: Shogo Nishida, et al.
Published: (2023-02-01) -
Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers
by: Thakur Ajit, et al.
Published: (2012-06-01) -
Engineering siRNA therapeutics: challenges and strategies
by: Syed Saqib Ali Zaidi, et al.
Published: (2023-10-01) -
Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition
by: Alexey Berezhnoy, et al.
Published: (2012-01-01)